Patents Examined by Brian McDowell
  • Substituted pyrazolopyrimidinylamino-indazoles
    Patent number: 9556181
    Abstract: The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of formula I, below, as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients wherein R1a, R1b, R1c, and R2 are defined herein.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: January 31, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Klar, Lars Wortmann, Georg Kettschau, Florian Pühler, Philip Lienau, Detlev Sülzle
  • Dihydropyrido pyrimidine compounds as autotaxin inhibitors
    Patent number: 9550774
    Abstract: The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: January 24, 2017
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Robert Anthony Doti, Lance Allen Pfeifer, Bryan Hurst Norman
  • Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
    Patent number: 9550789
    Abstract: Provided herein are halogenated indole and benzofuran derivatives of isoquinuclidene and intermediates thereto, and processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (?) and (+) noribogaine, in substantially enantiomerically pure forms.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 24, 2017
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Mark Kinch
  • Kinase modulating compounds, compositions containing the same and use thereof
    Patent number: 9550781
    Abstract: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: January 24, 2017
    Assignees: Centaurus Biopharma Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Dengming Xiao, Jijun Li, Yan Zhu, Yuandong Hu, Huting Wang, Zhe Wang, Zanping Wang, Yongheng Wei, Yinghui Sun, Qiong Wu, Hui Zhang, Yong Peng, Fansheng Kong, Ying Sun, Hong Luo, Yongxin Han
  • Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
    Patent number: 9550785
    Abstract: The present invention relates to Compounds of formula (I) and salts thereof: wherein R1 is n-C3-6alkyl; R2 is hydrogen or methyl; R3 is hydrogen or C1-6alkyl, and m is an integer having a value of 0 to 3; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: January 24, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Bicyclic compounds as kinases inhibitors
    Patent number: 9550738
    Abstract: The present invention is directed to novel bicyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions. Novel bicyclic compounds disclosed herein include quinazolines shown in Formula I (X?N).
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: January 24, 2017
    Inventor: Dawei Zhang
  • Porphyrin photosensitive dye and photoelectric conversion device utilizing the same
    Patent number: 9546278
    Abstract: Disclosed is a porphyrin photosensitive dye, having the chemical formula: Each of L1 and L2 is independently R1 is C5-20 linear/branched alkyl group. R2 is C0-20 linear/branched alkyl group. R4 is C1-20 linear/branched alkyl group. Each of R3 and R5 is independently C1-20 linear/branched alkyl group or C1-20 linear/branched alkoxy group. Y1 is C3-20 cycloalkyl group. Each of a and b is independently an integer of 0 to 5. D is Each of R6 to R11 is independently C1-10 alkyl group. X1 is N, O, S, or Se. Each of c, d, and e is independently an integer of 0 to 5. A is Each of Z1 and Z2 is independently hydrogen, alkali metal, or quaternary ammonium salt —N(R12)4. R12 is C1-10 alkyl group. X2 is N, O, S, or Se.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 17, 2017
    Assignee: Industrial Technology Research Institute
    Inventors: Shu-Nung Chang, Chia-Hua Lee, Yung-Liang Tung
  • Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
    Patent number: 9540376
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 10, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Viktor Lakics, Anna Linsenmeier, Helmut Mack, Raimund Peter, Ana Lucia Relo, Lynette Smyth
  • Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
    Patent number: 9540383
    Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C4-6alkyl or C1-2alkoxyC1-2alkyl-; R2 is hydrogen or methyl; each R3 is hydroxy, halo or n-C1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: January 10, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Bicyclic dihydropyridone kinase inhibitors
    Patent number: 9533986
    Abstract: Provided are bicyclic dihydropyridone compounds for inhibiting of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: January 3, 2017
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Anjali Pandey, Yonghong Song, Qing Xu
  • Tetrazines and method of synthezising the same
    Patent number: 9533957
    Abstract: Provided herein, inter alia, are compositions and methods of synthesis and detection of tetrazines, e.g., a tetrazine of formula and diazonorcaradienes.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: January 3, 2017
    Assignee: The Regents of the University of California
    Inventors: Neal K. Devaraj, Jun Yang
  • Triterpenoids with HIV maturation inhibitory activity
    Patent number: 9527882
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 27, 2016
    Assignee: ViiV Healthcare UK (No.4) Limited
    Inventors: Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob Swidorski, Brian Lee Venables, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Richard A. Hartz, Li Xu, Zheng Liu
  • Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
    Patent number: 9522133
    Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: December 20, 2016
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stirn
  • Pyridazine derivatives and use thereof as medicaments for treating microRNA viral infection
    Patent number: 9522891
    Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 20, 2016
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
  • Pyrazole compounds as CB2 agonists
    Patent number: 9512132
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 6, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Nettekoven Matthias, Ricklin Fabienne, Roever Stephan, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Pyrazine derivatives as CB2 receptor agonists
    Patent number: 9512141
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist for use in the treatment of several disorders, such as pain, atherosclerosis and glaucoma.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: December 6, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Baledi Dhurwasulu, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Materials for organic electroluminescent devices
    Patent number: 9515266
    Abstract: Triphenylene derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices, one of example of which is represented by formula I. The invention furthermore relates to a process for the preparation of the triphenylene derivatives and to electronic devices comprising the triphenylene derivatives.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: December 6, 2016
    Assignee: Merck Patent GmbH
    Inventors: Anja Jatsch, Rémi Manouk Anémian, Bernd Schroeder, Arne Buesing, Philipp Stoessel, Christof Pflumm, Jonas Valentin Kroeber, Thomas Eberle
  • 5-aminocyclylmethyl-oxazolidin-2-one derivatives
    Patent number: 9505750
    Abstract: The invention relates to antibacterial compounds of formula I wherein one or two of U, V, W, and X represent N, the rest represent CH or, in the case of X, may also represent CRa wherein Ra is fluorine; R1 represents alkoxy, halogen or cyano; R2 represents H, CH2OH, CH2N3, CH2NH2, alkylcarbonylaminomethyl or triazol-1-ylmethyl; R3 represents H, or, when n is 1, R3 may also represent OH, NH2, NHCOR6 or triazol-1-yl; A represents CR4; K represents O, NH, OCH2, NHCO, NHCH2, CH2NH, CH2CH2, CH?CH, CHOHCHOH or CHR5; R4 represents H or together with R5 forms a bond, or also R4 can represent OH when K is not O, NH, OCH2 or NHCO; R5 represents OH or together with R4 forms a bond; R6 represents alkyl; m is 0 or 1 and n is 0 or 1; and G is as defined in the description; and to salts of such compounds.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: November 29, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Christian Hubschwerlen, Georg Rueedi, Jean-Philippe Surivet, Cornelia Zumbrunn Acklin
  • Azaheterocyclic compounds
    Patent number: 9493444
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: November 15, 2016
    Assignees: Merck Patent GmbH, Cancer Research Technology Limited
    Inventors: Kai Schiemann, Frank Stieber, Christina Esdar
  • Organometallic complex, and light-emitting element and display device using the organometallic complex
    Patent number: 9490436
    Abstract: Disclosed is an organometallic complex capable of variable phosphorescence characteristics and yellow emission at high luminance. The organometallic complex has a structure represented by a formula (G10), where at least one of R4, R5, R6, and R7 is a phenoxy group, M is a Group 9 metal or a Group 10 metal, and n is 2 when the central metal M is a Group 9 element, or n is 1 when the central metal M is a Group 10 element.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: November 8, 2016
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Nobuharu Ohsawa, Satoko Shitagaki, Satoshi Seo